ArticleDrug design, development and therapy2026
Toward Model-Informed Precision Dosing of Imipenem: Multicenter External Validation of Population Pharmacokinetic Models in Adult Critically Ill Patients.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Selecting the Most Robust Imipenem Pharmacokinetic Model Requires Paired Forecasts and Explicit Metric Weighting [Letter].Drug design, development and therapy · 2026Article
- Selecting the Most Robust Imipenem Pharmacokinetic Model Requires Paired Forecasts and Explicit Metric Weighting [Response to Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Model-informed individualized dosing of imipenem is required for critically ill patients due to high infection mortality and large pharmacokinetic (PK) variability. This study aims to externally evaluate the predictive performance of available imipenem pharmacokinetic (popPK) models to facilitate clinical application. Methods: A multicenter dataset of 152 ICU patients (201 concentrations) was used for the external validation of 9 popPK models. Model performance was investigated for prediction- and simulation-based diagnostics and Bayesian forecasting. The median relative prediction error (rPE Results: Model predictive performance exhibited heterogeneity. Priori prediction showed wide rPE Conclusion: Available imipenem popPK models for adult critically ill patients were unsatisfactory in predictive performance, and the Truong et al (2025) model performed best among all models. The integration of Bayesian forecasting with therapeutic drug monitoring (TDM) data significantly improved predictive accuracy, suggesting that the synergistic use of the popPK model and TDM may optimize clinical dosing decisions and potentially improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.